论文部分内容阅读
目的观察丹参注射液联合依达拉奉治疗急性脑梗死的临床效果。方法选择医院2015年6月-2016年6月收治的急性脑梗死患者88例,将其按照奇偶数字法随机分为观察组和对照组各44例。对照组给予依达拉奉治疗,观察组在对照组治疗的基础上给予丹参注射液治疗,比较2组治疗效果。结果治疗前2组日常生活能力量表(ADL)评分和美国卫生研究院的卒中量表(NIHSS)评分比较差异均无统计学意义(P>0.05),治疗后2组ADL评分均升高,NIHSS评分均下降,且观察组优于对照组,差异均有统计学意义(P<0.05)。观察组总有效率为97.73%高于对照组的81.82%,差异有统计学意义(P<0.05)。结论丹参注射液联合依达拉奉治疗急性脑梗死效果好,且安全性高,值得临床推广及应用。
Objective To observe the clinical effect of Danshen injection combined with edaravone in the treatment of acute cerebral infarction. Methods Eighty-eight patients with acute cerebral infarction who were admitted to the hospital from June 2015 to June 2016 were randomly divided into observation group (44 cases) and control group (44 cases). The control group was treated with edaravone. The observation group was treated with Danshen injection on the basis of the control group, and the treatment effect was compared between the two groups. Results There was no significant difference in ADL score between the two groups before treatment and the NIHSS score (P> 0.05). After treatment, the ADL scores of both groups were increased, NIHSS scores decreased, and the observation group than the control group, the difference was statistically significant (P <0.05). The total effective rate in the observation group was 97.73%, which was significantly higher than that in the control group (81.82%, P <0.05). Conclusion Salvia injection combined with edaravone in the treatment of acute cerebral infarction with good effect, and high safety, it is worthy of clinical promotion and application.